Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
281
Recruiting, any sponsor type, condition "type 2 diabetes"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting281
- Completed4,255
281 trials
Showing 1 to 25, recently updated first.
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 DiabetesPivotal-lookingRecruiting
City of Hope Medical CenterAcademic, hospital or other
NCT07061574 · 120 participants (planned) · Start Mar 10, 2026 · Primary completion Apr 15, 2030
Drug: Anti-thymocyte globulin (ATG); verapamil extended-release capsule and 1 more · For: Type 1 Diabetes; New Onset
Sites: Los Angeles, California; San Francisco, California; New Haven, Connecticut · 11 sites in all
- A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07881887 · 617 participants (planned) · Start Oct 22, 2026 · Primary completion Mar 2029
Drug: LY4167586; Placebo · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Rogers, Arkansas; Anaheim, California; Los Alamitos, California · 15 sites in all
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07881458 · 1,000 participants (planned) · Start Oct 16, 2026 · Primary completion Oct 2029
Drug: eloralintide and tirzepatide; Tirzepatide · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Tucson, Arizona; Escondido, California; Los Alamitos, California · 96 sites in all
- A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06945406 · 124 participants (planned) · Start May 16, 2025 · Primary completion Jul 2027
Drug: LY4057996 SC; LY4057996 IV and 6 more · For: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Sites: Neuss, Germany
Op-T LLCIndustry
NCT06964087 · 72 participants (planned) · Start Apr 23, 2026 · Primary completion May 31, 2027
Drug: OPT101 · For: Type I Diabetes
Sites: Birmingham, Alabama; Walnut Creek, California; Aurora, Colorado · 5 sites in all
- Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)Pivotal-lookingRecruiting
Viking Therapeutics, Inc.Industry
NCT07868939 · 560 participants (planned) · Start Nov 2026 · Primary completion Oct 2028
Drug: VK2735 Oral; Placebo Comparator · For: Weight Loss
Sites: Tucson, Arizona; Lake Forest, California; Ocoee, Florida · 19 sites in all
- Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)Pivotal-lookingRecruiting
Viking Therapeutics, Inc.Industry
NCT07868835 · 560 participants (planned) · Start Nov 2026 · Primary completion Jul 2028
Drug: VK2735; Placebo comparator · For: Weight Loss
Sites: Tucson, Arizona; Chula Vista, California; Lake Forest, California · 20 sites in all
- A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07754461 · 600 participants (planned) · Start Aug 24, 2026 · Primary completion Jan 17, 2028
Drug: Placebo; Survodutide · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Gilbert, Arizona; Paradise Valley, Arizona · 121 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07748208 · 40 participants (planned) · Start Nov 30, 2026 · Primary completion Jun 15, 2029
Drug: Inavolisib; Fulvestrant and 1 more · For: Breast Cancer; Diabetes Type II
Sites: Clovis, California; Torrance, California; Washington D.C., District of Columbia · 13 sites in all
Suzhou Siran Biotechnology Co.,Ltd.Industry
NCT07479862 · 40 participants (planned) · Start Apr 16, 2026 · Primary completion Apr 24, 2028
Drug: SA030 Injection; Matching Placebo · For: Obese; Overweight; T2DM (Type 2 Diabetes Mellitus)
Sites: Brisbane, Australia; Adelaide, Australia
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07064473 · 11,800 participants (planned) · Start Jul 22, 2025 · Primary completion Dec 14, 2029
Drug: Vicadrostat; Empagliflozin and 1 more · For: Diabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases
Sites: Anniston, Alabama; Fairhope, Alabama; Guntersville, Alabama · 1,142 sites in all
- Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)Pivotal-lookingRecruiting
Hudson BiotechIndustry
NCT07481747 · 2,539 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: Tirzepatide; Placebo · For: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Sites: Shenzhen, China
AstraZenecaAstraZeneca (AZN)
NCT07024823 · 192 participants (planned) · Start Jun 9, 2025 · Primary completion Jan 29, 2027
Drug: AZD4248; Placebo and 4 more · For: Chronic Kidney Disease
Sites: Glendale, California; Chicago, Illinois; Ann Arbor, Michigan · 5 sites in all
- A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 DiabetesPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07112872 · 330 participants (planned) · Start Aug 19, 2025 · Primary completion Feb 5, 2028
Drug: Tifeglipron; Semaglutide and 1 more · For: Type 2 Diabetes Mellitus
Sites: Tucson, Arizona; Lake Forest, California; Rancho Cucamonga, California · 51 sites in all
- QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyPivotal-lookingRecruiting
Huijie ZhangAcademic, hospital or other
NCT07775846 · 820 participants (planned) · Start Nov 3, 2026 · Primary completion Feb 28, 2029
Drug: empagliflozin; Finerenone and 4 more · For: Type 2 Diabetic Kidney Disease
Sites: Shanghai, China
- A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 DiabetesPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07896109 · 121 participants (planned) · Start Oct 22, 2026 · Primary completion Jul 26, 2028
Drug: NNC9836-0001; Placebo (NaCl) · For: Diabetes Mellitus, Type 2
Sites: Neuss, Germany
Universitas SriwijayaAcademic, hospital or other
NCT07928661 · 50 participants (planned) · Start Jul 29, 2026 · Primary completion Dec 2026
Drug: Proliverenol · For: Diabetes Mellitus, Type 2
Sites: Palembang, Indonesia
- A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07775404 · 351 participants (planned) · Start Aug 21, 2026 · Primary completion Apr 6, 2028
Drug: Elecoglipron; Placebo · For: Obesity; Overweight
Sites: Baotou, China; Beijing, China; Changde, China · 49 sites in all
- Permissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM)Recruiting
Ohio State UniversityAcademic, hospital or other
NCT07293715 · 44 participants (planned) · Start Feb 25, 2026 · Primary completion Jun 2027
Drug: Insulin · For: Pregnancy, High Risk; Type 1 Diabetes; Type 2 Diabetes
Sites: Columbus, Ohio
- Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or OverweightPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07871409 · 230 participants (planned) · Start Oct 15, 2026 · Primary completion Jun 16, 2027
Drug: Maridebart cafraglutide · For: Obesity; Overweight
Sites: San Diego, California; Miami, Florida; Orlando, Florida · 25 sites in all
Istanbul UniversityAcademic, hospital or other
NCT07924618 · 40 participants (planned) · Start Mar 1, 2026 · Primary completion Sep 17, 2027
Drug: Semaglutide; Tirzepatide · For: Type 2 Diabetes Mellitus; Obesity
Sites: Istanbul, Turkey (Türkiye)
- A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07776509 · 500 participants (planned) · Start Aug 24, 2026 · Primary completion Aug 9, 2028
Drug: Lenbelintide; Placebo · For: Obesity or Overweight; Weight-Related Comorbidity; With/Without Diabetes Mellitus, Type 2
Sites: Escondido, California; Lincoln, California; Walnut Creek, California · 96 sites in all
SanofiSanofi (SNY)
NCT07457580 · 60 participants (planned) · Start Mar 16, 2026 · Primary completion Nov 30, 2026
Drug: Teplizumab · For: Type 1 Diabetes
Sites: Leuven, Belgium; Bron, France; Paris, France · 16 sites in all
BayerBayer (BAYRY)
NCT06278207 · 50,000 participants (planned) · Start May 15, 2024 · Primary completion Sep 30, 2027
Drug: Finerenone (BAY 94-8862) · For: Chronic Kidney Disease; Type 2 Diabetes Mellitus
Sites: Many Locations, New Jersey; Berlin, Germany; Many Locations, Japan · 4 sites in all
- Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With MelanomaPivotal-lookingRecruiting
Biocon Biologics UK PLCIndustry
NCT07476326 · 120 participants (planned) · Start Sep 9, 2026 · Primary completion Aug 16, 2027
Drug: Bmab1700; Opdivo · For: Melanoma
Sites: Bento Gonçalves, Brazil; Ijuí, Brazil; Pará, Brazil · 46 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.